Effects of Inflammatory Response Genes on the Immune Microenvironment in Colorectal Cancer

Yachen Wang

Jilin University First Hospital

Ying Wang

Jilin University First Hospital

Guanghuan Shi

Jilin University First Hospital

Mingqing Liu

Jilin University First Hospital

Luping Zhang

Jilin University First Hospital

Weidan Zhao

Jilin University First Hospital

Yingli Zhang

Jilin University First Hospital

Nan Zhang (✉ zhangnan@jlu.edu.cn)

Jilin University First Hospital <https://orcid.org/0000-0003-2152-6274>

Xige Yang

Jilin University First Hospital

Research

Keywords: inflammatory response, tumor microenvironment, colorectal cancer, immune cell infiltration, risk score

Posted Date: August 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-793904/v1>

License: (cc) (i) This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Frontiers in Genetics on April 8th, 2022. See the published version at <https://doi.org/10.3389/fgene.2022.886949>.

Abstract

Background: The close relationship between colorectal cancer and inflammation has been widely reported. However, the relationship between colorectal cancer and inflammation at the genetic level is not fully understood. From a genetic perspective, this study explored the relationship between inflammation-related genes and the immune microenvironment in colorectal cancer.

Method: We identified prognostic genes, namely *CX3CL1*, *CCL22*, *SERPINE1*, *LTB4R*, *XCL1*, *GAL*, *TIMP1*, *ADIPOQ*, and *CRH*, by using univariate and multivariate regression analyses. A risk scoring model for inflammatory response was established, and patients in The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database were divided into two groups: high risk group and low risk group.

Result: The analysis showed that the prognosis of the two groups was significantly different, and the low-risk group had a higher survival rate and longer survival time. Pathways related to apoptosis, inflammatory response, and hypoxia were significantly enriched as shown via Gene Set Enrichment Analysis (GSEA). Activated dendritic cell infiltration was found in both the TCGA and GEO databases, and the *CCL21* gene played a significant role in the process of activated dendritic cell infiltration. *CCL21* gene was also positively correlated with inflammatory response, and the gene expression and risk score were significantly different between the two groups.

Conclusion: In summary, inflammatory response has a direct impact on patients with colorectal cancer in the prognosis and immune infiltration and further research studies on the inflammatory response can help in advancing the development of immunotherapy for colorectal cancer.

Introduction

Colorectal cancer is the third most common cancer in the world[1]. It is also one of the main causes of cancer deaths in both men and women globally[2]. The possible link between inflammation and tumors was first revealed in the 19th century by Rudolf Virchow[3]. Epidemiological and clinical studies have also shown that patients who have Crohn's disease and ulcerative colitis, the two major types of inflammatory bowel disease, are at increased risk of colorectal cancer (CRC)[4]. The gut is particularly rich in human microbes, and bacteria disrupt the homeostasis by activating immune signaling pathways, leading to an inflammatory environment[5]. Tumor microenvironment plays an important role in the growth and development of tumors[6, 7]. Inflammation can cause the aggregation and activation of immune cells, and the activated immune cells promote the proliferation of tumor cells by secreting pro-inflammatory cytokines and chemokines[8]. Therefore, the relationship between inflammatory response and the immune microenvironment of colorectal cancer has attracted much attention. In this study, we screened out the inflammatory response genes related to the prognosis of intestinal tumors and constructed an inflammatory response risk score model. Enrichment of the model-related pathways was examined. Furthermore, we screened out the genes which may influence immune cell infiltration using the

inflammatory response risk score model. The purpose of this study was to examine the relationship between inflammatory response and intestinal tumor immune microenvironment at the genetic level.

Materials And Methods

Data sources

RNA sequences and clinical data of relevance in this study were obtained from the TCGA and GEO (GSE39582) databases. GSE39582 contains the largest sample size of CRC patients with the most complete clinical information.

Construction of the PPI network

We used a String database to construct the PPI network of genes related to inflammatory response.

Construction and grouping of inflammatory response models

We downloaded the genes related to inflammatory response, and then screened for the genes associated with the prognosis of colorectal cancer. The expression level of each gene in the TCGA and GEO databases was multiplied by the expression coefficient, followed by calculation of the risk score for each patient. For further analyses, the patients in the two databases were divided into high and low risk groups according to the median value of the risk score obtained from the TCGA database.

Survival analysis

There were 445 patients in the TCGA database, and the follow-up time was 12 years. There were 562 patients in the GEO database who were followed for 16 years. The 'survival' and 'SurvMiner' packages from R (4.0.3) language were used to analyze the prognosis of these patients. Kaplan-Meier method was used to draw the survival curves, and the log-rank test was used to test the statistical significance. $P < 0.05$ was considered significant.

ROC curve analysis

The 1-, 3-, and 5-year survival rates of patients in two databases were analyzed. The 'survival', 'SurvMiner', and 'timeROC' packages from R (4.0.3) language were used to analyze and calculate the area under the ROC curve (AUC). If the area under the curve of 1-, 3-, and 5-year survival rates gradually increases and exceeds 0.5, it indicates that the model has a high accuracy for predicting the survival of patients. The survival of the two groups was represented by a risk column and risk curve.

Heat map

The heatmap representing gene expression in this experiment was drawn by the 'PheatMap' package of R (4.0.3) language.

Cox regression analysis

Survival kit of R (4.0.3) language was used to analyze the inflammatory response genes that were significantly correlated with prognosis, and age, sex, T, N, M, and risk score were used for single-factor and multi-factor prognostic analyses.

Gene set enrichment analysis

We downloaded and extracted the genes associated with inflammation from the Gene Set Enrichment Analysis (GSEA) website. Gene sets with NOM $P < 0.05$ and FDR $Q < 0.06$ were considered to have statistical significance.

Analysis of the correlation between genes and inflammatory response

We downloaded the genes involved in regulating immune cells and screened for the ones that play a crucial role in inflammatory response. The 'ggplot2', 'GGPUBR', and 'ggExtra' packages of R (4.0.3) language were then used to analyze the correlation between these genes and inflammatory response, as well as their expression between the high and low risk groups.

Results

1. Extraction and screening of inflammatory response-related genes

We downloaded the Ontology gene set from the Gene Set Enrichment Analysis (GSEA) website and extracted the inflammatory response-related genes from the data set. We used the STRING protein-protein interaction (PPI) to establish the relationship between the proteins of the inflammatory response-related genes (Fig. 1A). Because of the large number of genes related to the inflammatory response, we selected 301 genes which were the largest number of adjacent nodes for subsequent gene screening (Fig. 1B). Next, we downloaded gene expression data and clinical information of intestinal tumors from the Cancer Genome Atlas (TCGA) database and extracted the expression levels of inflammatory response-related genes. Cox univariate analysis was used to screen out genes related to CRC prognosis (Fig. 1C). Since there were several genes related to prognosis, we selected the genes with $P < 0.03$ for subsequent modeling. *CCL22* and *CCRL2* were identified as low risk genes, while *CX3CL1*, *CD36*, *SERPINE1*, *LTB4*, *XCL1*, *GAL*, *TIMP1*, *ADIPOQ*, *S1PR3*, and *CRH* were identified high-risk genes. We included these genes in subsequent Cox multivariate regression analysis. The final prognosis model was constructed using *CX3CL1*, *CCL22*, *SERPINE1*, *LTB4R*, *XCL1*, *GAL*, *TIMP1*, *ADIPOQ*, *CRH*, and *CCL22* which was a low-risk gene (Fig. 1D).

2. Effects of inflammatory response-related genes on prognosis

Multivariate Cox regression analysis revealed nine inflammatory response genes which were related to the prognosis of colorectal cancer and were subsequently used to construct the prognosis model. The risk score for each patient was obtained by multiplying the amount of gene expression by the corresponding regression coefficients (0.3864, -1.111, 0.2468, 0.6110, 0.7304, 0.2915, 0.4683, 0.2706, and 2.198 for *CX3CL1*, *CCL22*, *SERPINE1*, *LTB4R*, *XCL1*, *GAL*, *TIMP1*, *ADIPOQ*, and *CRH* respectively). The median risk score of the patients in the TCGA and GEO databases as the standard, the patients were divided into high and low-risk groups.

Results of survival analysis for the two groups of patients is shown in Figs. 2A and B. Significant differences in the survival were observed between the high-risk and low-risk groups ($P < 0.05$). The area under the receiver operating characteristic (ROC) curve of the TCGA database and GEO database was greater than 0.05 (Fig. 2C, D). However, the area under the curve did not increase with the increase in follow-up time for either the TCGA or GEO databases. This shows that the prediction model has some issues regarding the accuracy of prognosis and needs improvement. In order to observe the survival of the patients in the high and low risk groups more intuitively, we used a risk histogram to display the survival status of patients in the TCGA and GEO databases (Fig. 3A, B). Patients in the high-risk group had lower survival rates than those in the low-risk group, indicating that our model can distinguish the high-risk group from the low-risk group. Next, we analyzed the relationship between the prognosis-related inflammatory response genes in the model (Fig. 3C, D). The relationship between the risk score and survival rate of patients is illustrated by risk curves in Fig. 3 (E and F plotted the risk scores of the patients in the high and low risk groups, respectively). Patients in the medium-high risk group lived shorter lives than those in the low-risk group (Fig. 3G, H), and with increasing time, the number of deaths also decreased. Finally, by using thermography, we evaluated the expression of the genes in the high and low risk groups in the model (Fig. 3I, J).

3. Effect of different clinical characteristics on the prognosis of CRC

Different clinical characteristics have different effects on the prognosis of patients with CRC. Along with the risk score obtained from the model, we analyzed the influence of different clinical characteristics on the prognosis of patients with CRC. First, Cox univariate regression analysis was used to determine the association between clinical features and the prognosis of patients from the two databases (Fig. 4A, B). Sex had no effect on the prognosis of patients, whereas other factors had an impact on the prognosis and were all high-risk factors. The risk score of the prediction model in the TCGA and GEO databases was also less than 0.05, which indicates that the risk score is related to prognosis of patients. Multivariate regression analysis of these factors showed that age, T, M, N, and risk score were all significant independent prognostic factors ($P < 0.05$) (Fig. 4C, D). Next, we observed that there was a difference in the expression of inflammatory response-related genes between different T stages (Fig. 4E, F). We found a significant difference in the expression of *SERPINE1* between different T stages ($P < 0.05$). Figures 4G and H are thermograms demonstrating the expression of the inflammatory response-related genes between different T stages in the two databases.

4. Enrichment of inflammation related gene pathways in the high and low risk groups

There were also differences in the enrichment of inflammatory response-related genes between the high and low risk groups. In order to understand the enrichment of pathways, GSEA software was used to analyze the pathways in the two risk groups. The high-risk groups in the TCGA and GEO databases demonstrated enrichment of a large number of apoptotic, hypoxia and inflammation related pathways, including apoptosis, hypoxia, IL-2-STAT5 signaling, IL-6-JAK-STAT3- signaling, and the P53-pathway (Fig. 5A). The enriched pathways in the low-risk group were mostly related to oxidative phosphorylation and peroxidation including E2F-target, oxidative-phosphorylation, peroxisomes, PI3K-AKT-mTOR signaling, and reactive-oxygen-species pathways (Fig. 5B).

5. Infiltration of immune cells

Inflammation often causes the infiltration of immune cells. Therefore, we studied the infiltration of immune cells in each risk group in the TCGA and GEO databases. Figures 6A and B respectively show the infiltration of immune cells in the high-risk groups and low-risk groups. In the TCGA database, the infiltration of 11 kinds of immune cells was significantly different between the high-risk and low-risk groups (Fig. 6C, $P < 0.05$). In the GEO database, the infiltration of one kind of immune cell was different between the high-risk and low-risk groups. Activated dendritic cells had different infiltration in the two databases. We downloaded immune related genes from the website of Tracking Tumor Immunophenotype and screened out the genes that regulate the activation of dendritic cells. We created heat maps (Fig. 7A, B) to show the expression of genes regulating the infiltration of dendritic cells in the TCGA and GEO databases in the high and low risk groups. The expression of the *CCL21* gene was significantly different between the two databases ($P < 0.05$). A correlation curve between *CCL21* gene expression and the risk score was drawn, which revealed that *CCL21* gene expression was positively correlated with the risk score. Additionally, the expression of *CCL21* gene was different between the high-risk and low-risk groups (Fig. 7C, D).

Discussion

During tumor development, changes observed in the tumor sites resemble chronic inflammation, a process described as 'a tumor is an unhealed wound' that promotes tumor survival[9]. Studies have shown that chronic inflammation is the leading cause of many cancers in humans[10]. Although inflammation can be used as a strategy against microbes, it is also thought to be a marker of cancer and plays a key role in tumorigenesis. Inflammatory response plays a decisive role in different stages of tumor progression, including initiation, promotion, malignant transformation, invasion, and metastasis[9], and can promote carcinogenesis by inducing gene mutations, stimulating angiogenesis and cell proliferation, or inhibiting cell apoptosis[11]. Inflammation-related genes are involved in these processes and act on corresponding pathways or regulate immune cells. Our study screened the inflammatory response genes associated with CRC and identified the core genes, among which *CX3CL1*, *CCL22*,

SERPINE1, *LTB4R*, *XCL1*, *GAL*, *TIMP1*, *ADIPOQ*, and *CRH* were closely related to the prognosis of patients. *CX3CL1* can induce the ERK pathway and cell proliferation, and also plays a specific tumor promoter role in breast cancer expressing *ERBB2*[12]. *CCL22* is a chemokine that is highly expressed in tumors, and promotes tumor growth, in addition to playing a role in tumor-related immunosuppression[13]. *SERPINE1* and *TIMP1* promote the migration and invasion of tumor cells[14, 15]. *SERPINE1* may also promote the invasion and metastasis of colorectal cancer[16]. *LTB4R* is a potent chemoattractant involved in inflammatory and immune responses to the paeoniflora-like signaling pathway[17], which is involved in all inflammatory diseases[18]. *XCL1* promotes antitumor activity[19], and *XCL1* expression is also significantly related to the number of tumor infiltrating CD8 + T cells as well as the expression of *PD-L1* in tumor cells[20]. *GAL* methylation status may be an important marker for predicting clinical prognosis in patients who are with head and neck squamous cell carcinoma[21]. *ADIPOQ* gene play a role in chronic inflammation and cancer[22]. *CRH* expression is associated with the advanced stage of ovarian cancer[23]. It can be seen that these inflammatory response-related genes are closely related to tumors. Accordingly, we chose these nine genes to build an inflammatory model.

Inflammatory responses are associated with poor prognosis in a variety of tumors[23–25]. In order to further examine the relationship between the model and prognosis of patients, we evaluated the prognosis of patients by taking the product of the expression level and expression coefficient of the nine genes in the model in the two databases as the risk score. Significant differences in prognosis were found in the high-risk and low-risk groups, and patients in the low-risk group lived significantly longer than those in the high-risk group. However, in the process of using ROC curve to evaluate the accuracy of survival analysis, we found that the AUC value did not change much with the extension of time in the TCGA and GEO databases. This indicates that the accuracy of the ROC curve to evaluate survival was not ideal, which may be related to the following factors: First, the survival rate of CRC is 73.8% (70.0% for rectal cancer, 75.9% for colon cancer)[26], five- year survival rate is 68.4%[27], and average survival time is 142.17 ± 21.60 months[26]. However, we evaluated 1-, 3-, and 5-years survival. Therefore, the survival situation could not be accurately reflected. Second, the sample was relatively small. Third, TCGA and GEO databases were selected for this study, and the predictive and prognostic accuracy of this model needs to be verified using multiple databases. Lastly, adjuvant therapies such as surgery and chemoradiotherapy also have an impact on the prognosis of patients[26]. This study analyzed the impact of age, sex, T, M, N stage, and risk score on the prognosis of patients, and found that the risk score had a corresponding impact on the prognosis of patients in both databases. However, in the multivariate analysis, the *P* value of the risk score in the GEO database was > 0.05 , indicating that the risk score could not be used as an independent prognostic factor. On further examination, we found that all colorectal cancer types in the GEO database were adenocarcinomas, and the samples were all from France. Because of the limitations of tumor types and sample sources, the results may not accurately reflect the effect of inflammatory response on prognosis of colorectal cancer patients. Some patients had received chemotherapy, and the prognosis of CRC patients is related to the depth of tumor invasion, presence of lymph node metastasis[28], presence of other diseases, presence of venous or lymphatic invasion, tumor grade[29], and genetic factors. These factors were not taken into account in this study, which is a limitation.

Furthermore, by using GSEA enrichment analysis to study the pathway enrichment in the high-risk groups and low-risk groups in the two databases. The study showed that the enriched pathways were mostly associated with hypoxia, inflammatory factors, and apoptosis.

Hypoxia and inflammation are closely related[30]. The inflammatory environment itself tends to be hypoxic[31], possibly because the metabolically active cells such as neutrophils migrating from the peripheral blood to the inflammatory tissue consume a large amount of energy[32, 33], and increase the oxygen demand[34]. Moreover, inflammation often leads to activation of the cellular hypoxia response pathways[35]. Infection activates keratinocytes, macrophages, dendritic cells, and other cells, leading to the production of inflammatory cytokines[36, 37]. Hypoxia also increases circulating proinflammatory cytokine levels[38]. Tumor development has been shown to be associated with the inactivation of apoptosis[39]. The downregulation of the tumor suppressor gene p53 can lead to reduced cell apoptosis and promote tumor growth[40], which are associated with many cancers[41, 42]. Some scientists also believe that apoptosis drives the proliferation and metastasis of tumor cells[43]. Thus, there is a close relationship between inflammatory response, inflammatory factors, and apoptosis.

The immune system plays a decisive role in the initial inflammatory response to infection and injury and is the main driver of the inflammatory protective response[44]. Therefore, the inflammatory response often leads to the infiltration of immune cells. In our study, the infiltration of 11 types of immune cells including activated dendritic cells, macrophages M0, macrophages M1, neutrophils, activated natural killer (NK) cells, NK cells, plasma cells, CD4 memory T cells, helper T cells, CD8 T cells, and regulatory T cells was significantly different between the high-risk and low-risk groups in the TCGA database. However, only the infiltrates of activated dendritic cells in the GEO database were significantly different in the high and low risk groups. Subsequently, the genes regulating activated dendritic cells were screened, and it was found that the expression of *CCL2* gene was different in the groups with high and low risk in the TCGA and GEO databases. Other studies have also shown that the *CCL2* gene is associated with inflammatory responses. *CCL2* is a chemokine that attracts and activates monocytes[45]. *CCL2* plays a crucial role in tumor cell growth, metastasis, and host immune response[46]. Additionally, *CCL2* has been shown to have both tumor stimulating and antitumor effects. Recent studies have suggested that *CCL2* plays a major role in tumor progression and metastasis[47]. *CCL2* can enhance the migration and invasion ability of prostate cancer cells[48], as well as induce the invasion of liver cancer cells[46]. High levels of *CCL2* expression in various types of tumors are also associated with poor prognosis[49]; for example, the increased level of *CCL2* expression is related to poor prognosis in breast cancer patients[50, 51]. Although many studies have elaborated the relationship between inflammatory response and colorectal cancer from the perspective of genetics and pharmacology, few articles have explored the relationship between inflammatory response-related genes and CRC at the genetic level. This study analyzed the relationship between inflammatory response-related genes and colorectal cancer at the genetic level, which can facilitate further research on colorectal cancer.

In conclusion, inflammatory response plays a significant role in the prognosis of CRC patients and in the tumor immune microenvironment. Understanding the relationship between inflammatory response and

immune cells is conducive to the faster application of effective immunotherapy for CRC treatment in the clinic, leading to an improvement in the prognosis of colorectal cancer patients.

Abbreviations

TCGA: The Cancer Genome Atlas; GEO: Gene Expression Omnibus; GSEA: Gene Set Enrichment Analysis; CRC: colorectal cancer; AUC: area under the ROC curve; PPI: protein-protein interaction; NK: natural killer;

Declarations

Ethics approval and consent to participate

The research didn't involve animal experiments, human specimens and no ethics related issues.

Consent for publication

All authors have read and approved the content and agree to submit for consideration for publication in the journal.

Availability of data and materials

All data was obtained from The Cancer Genome Atlas (TCGA, <https://tcgadata.nci.nih.gov/tcga/>) and Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>).

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by Finance Department of Jilin (2018SCZWSZX-039) and Health Department of Jilin(2015Q011) and Finance Department of Jilin(JLSWSRCZX2020-083) and The National Natural Science Foundation of China(81772055) and Science and Technology Department of Jilin Province(20170623092TC-11) and Key research project of Science and Technology Department of Jilin Province(20130206063YY) .

Authors' contributions

Wrote the manuscript: YCW and YW. Conceived and designed the study: XGY and NZ. Collected the literature: GHS, MQL, LPZ, WDW and YLZ. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge the reviewers for their helpful comments on this study.

References

1. Stoffel EM, Yurgelun MB. Genetic predisposition to colorectal cancer: Implications for treatment and prevention. *Seminars in oncology*. 2016;43(5):536–42.
2. Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. *British journal of cancer*. 2016;115(3):273–80.
3. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science*. 2012;336(6086):1268–73.
4. Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? *World journal of gastroenterology*. 2011;17(26):3092–100.
5. Brennan CA, Garrett WS. Gut Microbiota, Inflammation, and Colorectal Cancer. *Annu Rev Microbiol*. 2016;70:395–411.
6. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. *The Lancet Oncology*. 2019;20(3):e175–86.
7. Strasser K, Birnleitner H. Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. 2019;8(2):e1537693.
8. Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. *International journal of molecular sciences*. 2019;20(18).
9. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell*. 2010;140(6):883–99.
10. Bernstein CN, Blanchard JF, Kliever E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer*. 2001;91(4):854–62.
11. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology*. 2004;126(2):451–9.
12. Tardáguila M, Mira E, García-Cabezas MA, Feijoo AM, Quintela-Fandino M, Azcoitia I, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. *Cancer research*. 2013;73(14):4461–73.
13. Wiedemann GM, Knott MM, Vetter VK, Rapp M, Haubner S, Fessler J, et al. Cancer cell-derived IL-1 α induces CCL22 and the recruitment of regulatory T cells. *Oncoimmunology*. 2016;5(9):e1175794.
14. Klimczak-Bitner AA, Kordek R, Bitner J, Musiał J, Szemraj J. Expression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancer. *Oncology letters*. 2016;12(5):4133–8.

15. Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T. et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. *Journal of experimental clinical cancer research: CR*. 2016;35(1):148.
16. Simone TM, Longmate WM, Law BK, Higgins PJ. Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury. *Advances in wound care*. 2015;4(6):321–8.
17. Wilson GA, Butcher LM, Foster HR, Feber A, Roos C, Walter L, et al. Human-specific epigenetic variation in the immunological Leukotriene B4 Receptor (LTB4R/BLT1) implicated in common inflammatory diseases. *Genome medicine*. 2014;6(3):19.
18. Peters-Golden M, Henderson WR, Jr. Leukotrienes. *N Engl J Med*. 2007;357(18):1841–54.
19. Chou WC, Hsiung CN, Chen WT, Tseng LM, Wang HC. A functional variant near XCL1 gene improves breast cancer survival via promoting cancer immunity. 2020;146(8):2182–2193.
20. Tamura R, Yoshihara K. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary. 2020;39(17):3541–3554.
21. Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, et al. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis. *Molecular carcinogenesis*. 2017;56(3):1107–16.
22. Divella R, Daniele A, Mazzocca A, Abbate I, Casamassima P, Caliandro C, et al. ADIPOQ rs266729 G/C gene polymorphism and plasmatic adipocytokines connect metabolic syndrome to colorectal cancer. *J Cancer*. 2017;8(6):1000–8.
23. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. *British journal of cancer*. 2007;97(5):637–45.
24. Sano Y, Kogashiwa Y, Araki R, Enoki Y, Ikeda T, Yoda T, et al. Correlation of Inflammatory Markers, Survival, and COX2 Expression in Oral Cancer and Implications for Prognosis. *Otolaryngology–head neck surgery: official journal of American Academy of Otolaryngology-Head Neck Surgery*. 2018;158(4):667–76.
25. Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. *Journal of translational medicine*. 2019;17(1):30.
26. Fatemi SR, Pourhoseingholi MA, Asadi F, Vahedi M, Pasha S, Alizadeh L, et al. Recurrence and Five - Year Survival in Colorectal Cancer Patients After Surgery. *Iranian journal of cancer prevention*. 2015;8(4):e3439.
27. Kong L, Peng J, Li J, Wang F, Li C, Ding P, et al. Prolonged surveillance of colorectal cancer patients after curative surgeries beyond five years of follow-up. *Annals of translational medicine*. 2019;7(21):608.

28. Haq AI, Schneeweiss J, Kalsi V, Arya M. The Dukes staging system: a cornerstone in the clinical management of colorectal cancer. *The Lancet Oncology*. 2009;10(11):1128.
29. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. *J Clin Pathol*. 2008;61(5):561–9.
30. Biddlestone J, Bandarra D, Rocha S. The role of hypoxia in inflammatory disease (review). *Int J Mol Med*. 2015;35(4):859–69.
31. Watts ER, Walmsley SR. Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. *Trends Mol Med*. 2019;25(1):33–46.
32. Borregaard N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. *J Clin Invest*. 1982;70(3):550–7.
33. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. *Cell*. 2003;112(4):453–65.
34. Rao P, Suvas S. Development of Inflammatory Hypoxia and Prevalence of Glycolytic Metabolism in Progressing Herpes. Stromal Keratitis Lesions. 2019;202(2):514–26.
35. Liu H, Wang Z, Yu S, Xu J. Proteasomal degradation of O-GlcNAc transferase elevates hypoxia-induced vascular endothelial inflammatory response. *Cardiovascular research*. 2014;103(1):131–9.
36. Mooney DP, O'Reilly M, Gamelli RL. Tumor necrosis factor and wound healing. *Annals of surgery*. 1990;211(2):124–9.
37. Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. *Nature*. 1986;323(6091):819–22.
38. Song TT, Bi YH, Gao YQ, Huang R, Hao K, Xu G, et al. Systemic pro-inflammatory response facilitates the development of cerebral edema during short hypoxia. *J Neuroinflamm*. 2016;13(1):63.
39. Xu CX, Jin H, Cho MH. Apoptosis and apoptosis-based therapy in lung cancer. *Anti-cancer Agents Med Chem*. 2009;9(9):952–7.
40. Bauer JH, Helfand SL. New tricks of an old molecule: lifespan regulation by p53. *Aging cell*. 2006;5(5):437–40.
41. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. *Breast cancer research: BCR*. 2002;4(2):70–6.
42. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. *Proc Natl Acad Sci USA*. 1990;87(19):7555–9.
43. Wang RA, Li QL, Li ZS, Zheng PJ, Zhang HZ, Huang XF, et al. Apoptosis drives cancer cells proliferate and metastasize. *J Cell Mol Med*. 2013;17(1):205–11.
44. Carrillo-Salinas FJ, Ngwenyama N, Anastasiou M, Kaur K, Alcaide P, Heart. Inflammation: Immune Cell Roles and Roads to the Heart. *Am J Pathol*. 2019;189(8):1482–94.
45. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. *Semin Cancer Biol*. 2004;14(3):149–54.

46. Zhuang H, Cao G, Kou C, Liu T. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway. *Oncol Rep.* 2018;39(1):21–30.
47. Li M, Knight DA, Smyth LAS. MJ, Stewart TJ. A role for CCL2 in both tumor progression and immunosurveillance. *Oncoimmunology.* 2013;2(7):e25474.
48. Natsagdorj A, Izumi K. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. 2019;110(1):279–288.
49. Yang Y, Zhai C, Chang Y, Zhou L, Shi T, Tan C, et al. High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma. *Urol Oncol.* 2016;34(5):238.e219-226.
50. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, et al. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology Medicine.* 2004;25(1–2):14–7.
51. Fang WB, Yao M, Jokar I, Alhakamy N, Berkland C, Chen J, et al. The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. *Breast cancer research treatment.* 2015;150(2):309–20.

Figures

Figure 2

Effect of the model on prognosis. (A, B) Patients with colorectal cancer were divided into high-risk group and low risk group using Kaplan Meier method (TCGA, GEO). The log-rank test was used to compare the survival time between the high-risk and low-risk groups (P values were less than 0.001 and equal to 0.013, respectively). (C, D) By using ROC curve to evaluate the accuracy of the prediction model. The area under the ROC curve of TCGA and GEO databases was greater than 0.5. However, the area under the ROC curves of 1-, 3- and 5-year survival did not increase with the increase in the follow-up time for either databases.

Figure 3

Survival rate and prognosis of patients using the model, along with the expression of genes in the model in the high-risk and low-risk groups. (A, B) Survival rates in the TCGA and GEO databases. (C, D) Relationship between the genes in the model. (E, F) Risk scores of patients in the TCGA and GEO databases. (G, H) Survival time of patients in the high and low risk groups in the TCGA and GEO

databases. (I, J) Expression of the genes in the model in the high and low risk groups of the TCGA and GEO databases.

Figure 4

Relationship between the risk model and different clinical traits. (A, B) Univariate prognostic analysis was performed on age, sex, T, N, M stage, and risk score of colorectal cancer patients in the TCGA and GEO databases. (C, D) Multivariate prognostic analysis was performed on age, sex, T, N, M stage, and risk

score of colorectal cancer patients in the TCGA and GEO databases. (E, F) Expression of genes between among T stages in the TCGA and GEO databases. (G, H) Heat maps of the expression of inflammatory response genes among different T stages in models in the TCGA and GEO databases.

Figure 5

Enrichment of pathways in the high-risk and low-risk groups. (A) Enriched gene sets in the hallmark gene collection by the high-risk score in the TCGA database. The lines with different colors represent different gene sets. The up-regulated genes are located near the origin of the coordinate on the left, while the down-regulated genes are located on the right side of the x-axis. Gene sets with NOM $p < 0.05$ and FDR $q < 0.06$ were statistically significant. Only a few major gene sets are shown. (B) Enriched gene sets in the hallmark collection by the high-risk score in the GEO database. Gene sets with NOM $p < 0.05$ and FDR $q < 0.06$ were statistically significant. Only a few major gene sets are shown. (C) Enriched gene sets in the hallmark collection by the low-risk score in the TCGA database. Only gene sets with NOM $p < 0.05$ and FDR $q < 0.06$ were considered statistically significant. Only a few major gene sets are shown. (D) Enriched gene sets in the hallmark collection by the low-risk score in the GEO database. Gene sets with NOM $p < 0.05$ and FDR $q < 0.06$ were statistically significant. Only a few major gene sets are shown.

Figure 6

Immune cell infiltration in high and low risk groups. (A, B) Thermography of inflammatory response-related gene risk scores and immune cell infiltration in the TCGA and GEO databases. (C, D) Infiltrating immune cells in the TCGA and GEO databases were significantly associated with the risk scores.

Figure 7

Relationship between immune cell regulatory genes and risk scores of genes associated with inflammatory response. (A, B) Heat maps of the expression of genes significantly related to immune cell regulation in different risk groups in TCGA and GEO databases (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$). (C, D) Correlation between CCL21 gene significantly associated with immune cell regulation and risk score in the TCGA and GEO databases. The blue line in the figure fitted the linear model between gene expression

and risk score of genes related to inflammatory response, and Pearson's coefficient was used to test the correlation. Box chart showed the difference in CCL21 gene expression between groups with high and low risk of inflammatory response related genes ($P < 0.05$).